Autogene cevumeran

Autogene cevumeran is an investigational messenger RNA vaccine being developed jointly by BioNTech and Genentech as a treatment to prevent the recurrence of cancer after surgery. It is an individualized neoantigen-specific immunotherapy, manufactured for each patient from mutations identified in that patient's own resected tumor, encoding as many as twenty neoantigens intended to teach the immune system to recognize and attack any remaining cancer cells. It has been studied primarily in resectable pancreatic ductal adenocarcinoma, a form of pancreatic cancer with a high rate of recurrence after surgery. In an early-phase trial, patients whose immune systems responded to the vaccine had not reached the eighteen-month mark for cancer recurrence, while patients who did not respond had a median recurrence-free survival of 13.4 months. As of its most recent studies it remained in clinical trials and had not received regulatory approval.